Zhitong Finance App learned that innovative drug concept stocks continued to rise. As of press release, Zaiding Pharmaceutical (09688) rose 6.35% to HK$20.98; Shiyao Group (01093) rose 5.71% to HK$9.17; Kingsley Biotech (01548) rose 5.55% to HK$26.4; and Hanson Pharmaceuticals (03692) rose 4.78% to HK$35.1.

According to the news, the license for innovative drugs to go overseas has entered the high-frequency implementation period. On August 10, a single three-pound deal was launched: BeiGene cooperated with Revolution Medicines to explore innovative cancer treatment plans and obtained exclusive development and commercialization rights for four clinical-stage drug candidates in some Asian markets; Cinda Biotech joined hands with Daiichi Sankyo to win the commercialization and promotion rights of Weifutai in the mainland China market; Gan Li Pharmaceutical used Menarini to promote self-developed GLP-1 innovative drugs into the European market.

Zhongtai Securities pointed out that since 2026, China's innovative pharmaceutical industry has gradually entered the value realization stage. The industry logic has moved from being catalyzed by BD events in the past to overseas commercialization, clinical data implementation, and continuous revenue contributions. Recent financial reports from leading overseas pharmaceutical companies have continued to verify the value of China's innovative assets, and MNC's strategic position on innovative drugs in China has gradually improved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.